These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25260887)

  • 1. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
    Hoy SM
    Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The winning formulation: the development of paclitaxel in pancreatic cancer.
    Ma WW; Hidalgo M
    Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
    Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
    BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
    Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer.
    De Luca R; Blasi L; Alù M; Gristina V; Cicero G
    Drug Des Devel Ther; 2018; 12():1769-1775. PubMed ID: 29950811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
    Roy V; LaPlant BR; Gross GG; Bane CL; Palmieri FM;
    Ann Oncol; 2009 Mar; 20(3):449-53. PubMed ID: 19087987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
    Bertocchi P; Abeni C; Meriggi F; Rota L; Rizzi A; Di Biasi B; Aroldi F; Ogliosi C; Savelli G; Rosso E; Zaniboni A
    Rev Recent Clin Trials; 2015; 10(2):142-5. PubMed ID: 25881637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
    Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
    Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
    Vishnu P; Roy V
    Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy evaluation of albumin-bound paclitaxel.
    Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
    Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
    Blair HA; Deeks ED
    Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
    Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
    Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
    Babiker H; Schlegel PJ; Hicks LG; Bullock AJ; Burhani N; Mahadevan D; Elquza E; Borad MJ; Benaim E; Peterson C; Heaton C; Ocean AJ
    Invest New Drugs; 2022 Feb; 40(1):81-90. PubMed ID: 34417914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
    Hoffman RM; Bouvet M
    Expert Opin Pharmacother; 2015 May; 16(7):943-7. PubMed ID: 25887245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.